أعرض في EDS

Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.

التفاصيل البيبلوغرافية
العنوان: Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.
المؤلفون: Lee HJ; Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Pham PC; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Hyun SY; Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Baek B; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Kim B; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Kim Y; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Min HY; Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.; Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea., Lee J; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea. jyleeut@snu.ac.kr., Lee HY; Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr.; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr.; Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr.
المصدر: Molecular cancer [Mol Cancer] 2023 Mar 08; Vol. 22 (1), pp. 47. Date of Electronic Publication: 2023 Mar 08.
نوع المنشور: Published Erratum
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: PubMed not MEDLINE; MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2002-
التعليقات: Erratum for: Mol Cancer. 2018 Feb 19;17(1):50. (PMID: 29455661)
References: Mol Cancer. 2018 Feb 19;17(1):50. (PMID: 29455661)
تواريخ الأحداث: Date Created: 20230317 Latest Revision: 20230319
رمز التحديث: 20230320
مُعرف محوري في PubMed: PMC10018920
DOI: 10.1186/s12943-023-01754-6
PMID: 36927387
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-4598
DOI:10.1186/s12943-023-01754-6